Skip to main content

Table 3 Cox regression of potential factors to predict survival

From: Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system

Cox regression Hazard (95 % CI) Univariate P Multivariate P
Age 1.02 (1.00–1.04) 0.239  
Sex‘ 0.76 (0.50–1.14) 0.179  
Karnofsky index 0.98 (0.95–0.99) 0.014* 0.037**
Resection/RFA‘ 0.90 (0.56–1.44) 0.658  
Oxaliplatin + 5-FU‘ 1.44 (0.91–2.26) 0.118  
Irinotecan + 5-FU‘ 1.41 (0.82–2.46) 0.216  
Capecitabine‘ 1.24 (0.79–1.94) 0.344  
Bevacizumab‘ 0.87 (0.58–1.30) 0.492  
Cetuximab‘ 1.26 (0.85–1.87) 0.243  
Overall chemotherapy lines 1.14 (0.94–1.37) 0.179  
UICC staging 1.01 (0.79–1.30) 0.286  
Tumor grading 0.90 (0.64–1.28) 0.434  
Lung metastases‘ 1.53 (0.85–2.74) 0.155  
Lymphatic metastases‘ 1.60 (0.91–2.80) 0.100* 0.204
Bone metastases‘ 2.51 (0.89–7.13) 0.083* 0.083
Hepatic tumor load 1.05 (1.03–1.06) <0.001* 0.001**
CEA serum level 1.00 (1.00–1.00) 0.002* 0.023**
CA19-9 serum level 1.00 (1.00–1.00) <0.001* <0.001**
Bilobar Y90 RE‘ 0.89 (0.45–1.77) 0.740  
Unilobar Y90 RE‘ 0.74 (0.35–1.55) 0.426  
Sequential lobar Y90 RE‘ 0.82 (0.40–1.66) 0.775  
Y90 RE sessions per patient 0.95 (0.72–1.24) 0.692  
Total activity per patient 1.00 (0.99–1.00) 0.276  
  1. Results in the univariate analysis (*p < 0.1) were included in the multivariate analysis (**p < 0.05). Binary factors are marked (‘), other variables are ordinal or continuous